Neoplasms Clinical Trial
— COLAPOfficial title:
Treatment as Usual vs. Additional Collaborative Advance Care Planning to Improve Quality of Life for Palliative Cancer Patients: a Randomized Controlled Trial
This study evaluates the effect of a collaborative advance care planning intervention on the
quality of life in palliative oncological patients. Research indicates, that talking about
wishes for end of life care and death, may improve the quality of life, but can be difficult
for involved parties.
The intervention especially developed for this study trys to reduce psychosocial barriers
that make conversations about these topics difficult. The study will measure the effect of
the intervention on patients and caregivers quality of life.
The study will give additional information about implementation of advance care planning
interventions in different care settings in a complex health care systems.
Status | Recruiting |
Enrollment | 280 |
Est. completion date | September 1, 2020 |
Est. primary completion date | January 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patient > 18 years - Patient with advance cancer in palliative setting - positive surprise question: the physician will not be surprised, if the patient died in the next 12 month - Patient is willing to take part in the study Exclusion Criteria: - Patients life expectancy below 3 month (estimated by physician) - Patients ECOG-status is > 3 - Patient is not able to speak German - Patient is incapacitated to give informed consent |
Country | Name | City | State |
---|---|---|---|
Germany | Philipps University | Marburg | |
Germany | Philipps University, Departement of Psychology, Division of Clinical Psychology and Psychtherapy | Marburg |
Lead Sponsor | Collaborator |
---|---|
PD. Dr. med. Carola Seifart | Department of Clinical Psychology and Psychotherapy, German Federal Ministry of Education and Research, Philipps University Marburg Medical Center |
Germany,
Ando M, Morita T, Akechi T, Okamoto T; Japanese Task Force for Spiritual Care. Efficacy of short-term life-review interviews on the spiritual well-being of terminally ill cancer patients. J Pain Symptom Manage. 2010 Jun;39(6):993-1002. doi: 10.1016/j.jpainsymman.2009.11.320. — View Citation
Bollig G, Rosland JH, Gjengedal E, Schmidt G, May AT, Heller A. A European multicenter study on systematic ethics work in nursing homes. Scand J Caring Sci. 2017 Sep;31(3):587-601. doi: 10.1111/scs.12373. Epub 2016 Aug 26. — View Citation
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993 Mar;11(3):570-9. — View Citation
Chochinov HM, Hack T, Hassard T, Kristjanson LJ, McClement S, Harlos M. Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life. J Clin Oncol. 2005 Aug 20;23(24):5520-5. — View Citation
Cohen L, Parker PA, Vence L, Savary C, Kentor D, Pettaway C, Babaian R, Pisters L, Miles B, Wei Q, Wiltz L, Patel T, Radvanyi L. Presurgical stress management improves postoperative immune function in men with prostate cancer undergoing radical prostatectomy. Psychosom Med. 2011 Apr;73(3):218-25. doi: 10.1097/PSY.0b013e31820a1c26. Epub 2011 Jan 21. — View Citation
Heckel M, Bussmann S, Stiel S, Weber M, Ostgathe C. Validation of the German Version of the Quality of Dying and Death Questionnaire for Informal Caregivers (QODD-D-Ang). J Pain Symptom Manage. 2015 Sep;50(3):402-13. doi: 10.1016/j.jpainsymman.2015.03.020. Epub 2015 Jun 14. — View Citation
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. — View Citation
Lumbeck, Gudrun; Brandstätter, Monika; Geissner, Edgar (2012): Erstvalidierung der deutschen Version des "Inventory of Complicated Grief" (ICG-D). In: Zeitschrift für Klinische Psychologie und Psychotherapie 41 (4), p. 243-248.
Mack JW, Nilsson M, Balboni T, Friedlander RJ, Block SD, Trice E, Prigerson HG. Peace, Equanimity, and Acceptance in the Cancer Experience (PEACE): validation of a scale to assess acceptance and struggle with terminal illness. Cancer. 2008 Jun;112(11):2509-17. doi: 10.1002/cncr.23476. — View Citation
Markowitz JC, Kocsis JH, Fishman B, Spielman LA, Jacobsberg LB, Frances AJ, Klerman GL, Perry SW. Treatment of depressive symptoms in human immunodeficiency virus-positive patients. Arch Gen Psychiatry. 1998 May;55(5):452-7. — View Citation
Mehnert, Anja; Müller, Diana; Lehmann, Claudia; Koch, Uwe (2006): Die deutsche Version des NCCN Distress-Thermometers. In: Zeitschrift für Psychiatrie, Psychologie und Psychotherapie 54 (3), S. 213-223. DOI: 10.1024/1661-4747.54.3.213.
Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM, McLaughlin WP, Wei JT. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005 Apr 20;23(12):2772-80. — View Citation
Prigerson HG, Maciejewski PK, Reynolds CF 3rd, Bierhals AJ, Newsom JT, Fasiczka A, Frank E, Doman J, Miller M. Inventory of Complicated Grief: a scale to measure maladaptive symptoms of loss. Psychiatry Res. 1995 Nov 29;59(1-2):65-79. — View Citation
Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996 Mar;34(3):220-33. — View Citation
Weitzner MA, Jacobsen PB, Wagner H Jr, Friedland J, Cox C. The Caregiver Quality of Life Index-Cancer (CQOLC) scale: development and validation of an instrument to measure quality of life of the family caregiver of patients with cancer. Qual Life Res. 1999;8(1-2):55-63. — View Citation
Weitzner MA, McMillan SC. The Caregiver Quality of Life Index-Cancer (CQOLC) Scale: revalidation in a home hospice setting. J Palliat Care. 1999 Summer;15(2):13-20. — View Citation
Zeng L, Bedard G, Cella D, Thavarajah N, Chen E, Zhang L, Bennett M, Peckham K, De Costa S, Beaumont JL, Tsao M, Danjoux C, Barnes E, Sahgal A, Chow E. Preliminary results of the generation of a shortened quality-of-life assessment for patients with advanced cancer: the FACIT-Pal-14. J Palliat Med. 2013 May;16(5):509-15. doi: 10.1089/jpm.2012.0595. Epub 2013 Apr 16. — View Citation
* Note: There are 17 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Functional Assessment of Cancer Therapy scale (FACT-G; Cella, Tulsky, Gray, et al., 1993) | Quality of life (QOL). Self-rating measurement; four subscales: physical well-being (7-items, score range 0-28), social/ family well-being (7-items, score range 0-28), emotional well being (6-items, score range 0-24) and functional well being (7-items, score range 0-28), one total score (sum of the four subscale scores; score range of 0-108). Higher subscale and total scores indicate better QoL. | 60 weeks; Baseline, 8 weeks (after randomisation: a.r.), 16 weeks (a. r.); every two month for the following 8 month or till death (if occuring within one year after randomisation) | |
Secondary | 12-Item Short Form Health Survey (SF-12; Ware, Kosinski, Keller, 1996) | QOL of patients. Two subscales of health related quality of life (QOL): physical health and mental health (score range:0-100). Higher scores indicate better QoL. | 60 weeks; Baseline, 8 weeks (after randomisation: a.r.), 16 weeks (a. r.); every two month for the following 8 month or till death (if occuring within one year after randomisation) | |
Secondary | Functional assessment of chronic illness therapy - palliative care- 14 items (FACIT-Pal-14; Zeng et al. 2014) | QoL of palliative care patients. A higher score indicate better QoL. | 60 weeks; Baseline, 8 weeks (after randomisation: a.r.), 16 weeks (a. r.); every two month for the following 8 months or till death (if occuring one year after randomisation) | |
Secondary | National Comprehensive Cancer Network Distress Thermometer (Mehnert et al. 2006) | scale from 0 to 10 assessing overall psycho social distress, was specifically developed for oncological patients. | 16 weeks; Baseline, 8 weeks (after randomisation: a.r.), 16 weeks (a. r.) | |
Secondary | Peace, Equanimity, and Acceptance in the Cancer Experience (PEACE-Scale, Mack et al. 2008) | The scale was developed to assess the acceptance of the disease and the inner peace of patients. 12 items, two subscales: inner acceptance of disease (score 0-20 high number indicating high acceptance), inner conflict with disease (score 0-28 high score indicating more conflict) |
16 weeks; Baseline, 8 weeks (after randomisation: a.r.), 16 weeks (a. r.) | |
Secondary | Barriers of communication (patients) | This self developed questionnaire will try to assess the barriers of communication of patients and caregivers concerning topics like end of life care and death. 25 items, 6 point likert scale. High score indicating low barriers of communication (some reverse scored items). The scale will be validated in the study. |
8 weeks; Baseline, 8 weeks (after randomisation: a.r.) | |
Secondary | Patient Health Questionnaire (PHQ-9; Kroenke et al. 2001) | Assesses severe symptoms of depression based on criteria by the DSM IV. 9 items, sumscore (0-27), a high sumscore indicates a high level of depression | 16 weeks; Baseline, 8 weeks (after randomisation: a.r.), 16 weeks (a. r.) | |
Secondary | Expectations about treatment of patients (self-developed, visual analogues scale) | These three self-developed items assess descriptive 1. the expectations patients have towards their cancer therapy (e.g. prolonging of life, improvement of QoL) and 2. the importance of prolonging of life & improvement of QoL (two visual analogues scales) | 16 weeks; Baseline, 16 weeks (a. r.) | |
Secondary | Existence of ACP directive | Patients will be asked, if they have completed and advance healthcare directive or took part in an ACP-process. Purely descriptive (Advance directive yes vs. no) | 60 weeks; Baseline, 8 weeks (after randomisation: a.r.), 16 weeks (a. r.); 1 year (a.r.) or after death (if occuring one year a. r.) | |
Secondary | Caregiver Quality of Life Index - Cancer Scale (CQOLC; Weitzner et al., 1999) | Assessment of cancer caregivers QoL and has been validated in curative and palliative settings. 34 items, 5 point likert scale, high score indicating low QoL (some items reverse scoreed) |
60 weeks; Baseline, 8 weeks (after randomisation: a.r.), 16 weeks (a. r.); 1 year (a.r.) or after death of patient (if occuring one year a. r.) | |
Secondary | 12-Item Short Form Health Survey (SF-12; Ware, Kosinski & Keller,1996) | QOL of caregivers. Two subscales of health related quality of life (QOL): physical health and mental health (score range:0-100). Higher scores indicate better QoL. | 60 weeks; Baseline, 8 weeks (after randomisation: a.r.), 16 weeks (a. r.); 1 year (a.r.) or after death of patient (if occuring one year a. r.) | |
Secondary | Patient Health Questionnaire - (PHQ-9; Kroenke et al., 2002) | Depression of caregivers. Assesses severe symptoms of depression based on criteria by the DSM IV. 9 items, sumscore (range 0-27), a high sumscore indicates a high level of depression |
Baseline | |
Secondary | Quality of Dying and Death Questionnaire for Informal Caregivers (QODD-D-Ang; Heckel et al. 2015) | The QODD-questionnaire (Qualitiy of dying and death) assesses the quality of the deceasing phase from a caregivers perspective.QODD-D-Ang total score (sumscore range 0-100); higher scores indicate better Quality of dying and death. | 4-8 weeks after death of patient (if occuring within one year after randomisation) | |
Secondary | Barriers of communication (caregiver) | This self developed questionnaire will try to assess the barriers of communication of patients and caregivers concerning topics like end of life care and death. The scale will be validated in the study. Higher scores indicate more barriers of communication. | 8 weeks; Baseline, 8 weeks (after randomisation: a.r.), | |
Secondary | Expectations about treatment of patients (self-developed, visual analogues scales) | These three self-developed items assess descriptive 1. the expectations caregivers have towards their relatives cancer therapy (e.g. prolonging of life, improvement of QoL) and 2. the importance of prolonging of life & improvement of QoL (two visual analogues scales) | 16 weeks; Baseline, 16 weeks (a. r.) | |
Secondary | Inventory of Complicated Grief (Lumbeck, Brandstätter, & Geissner, 2013; Prigerson et al., 1995) | Complicated grief, 19 items, sumscore (0-76, cut-off >25) | 4-8 weeks after death of patient (if occuring within one year after randomisation) | |
Secondary | Existence of ACP directive | Caregivers will be asked, if the patient has completed and advance healthcare directive or took part in an ACP-process. Purely descriptive (Advance directive yes vs. no) | 4-8 weeks after death of patient (if occuring within one year after randomisation) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Completed |
NCT02909348 -
Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab
|